AOU Maggiore della Carità di Novara - Sindromi mielodisplastiche

Registro MDS FISM

Registro Piemontese delle Sindromi Mielodisplastiche

Syros SY1425

A randomized, double-blind- placebo-controlled phase 3 study of SY-1425 plus Azacitidine versus placebo plus Azacitidine in newly diagnosed, RARA-positive adult patients with higher-risk Myelodysplastic Syndrome

QoL-ONE Phoenix

Efficacy and safety of Luspatercept for the treatment of anemia due to Myelodysplastic Syndromes with del5q refractory/resistant/intolerant to prior treatments, who require red blood cell transfusion

MAXILUS

A Phase 3b, open-label study evaluating the efficacy and safety Luspatercept (BMS-986346/ACE-536) initiated at maximum approved dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk who require RBC transfusions

ASTX030-01

A multi-phase, pharmacokinetics, safety, and efficacy study of ASTX030 (Azacitidine e Cedazurine) as monotherapy in subjects with myeloid neoplasm or in combination with venetoclax in subjects with AML or MDS

GLORA-4

An international, multicenter, randomized, double-blind, placebo-controlled, pivotal registration Phase III study of APG-2575 (Lisaftoclax) in combination with Azacitidine (AZA) in patients with newly diagnosed higher risk Myelodysplastic Syndrome (GLORA-4)